TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33753319

Group type: EXPERIMENTAL
Intervention: Bilateral ultrasound-guided Erector Spinae Plane Block (ESPB) with 30 mL of 0.375% ropivacaine on each side
Number of subjects: 55

Group type: COMPARATOR
Intervention: Standard of care (postoperative muscular infiltration with 30 mL of 0.75% ropivacaine)
Number of subjects: 55
Study: 34664152

Group type: EXPERIMENTAL
Intervention: Deception about occupation
Number of subjects: 644

Group type: EXPERIMENTAL
Intervention: Deception about attractiveness
Number of subjects: 644

Group type: EXPERIMENTAL
Intervention: Deception about volunteerism
Number of subjects: 644
Study: 32023574

Group type: EXPERIMENTAL
Intervention: Visually guided laser balloon ablation (VGLB)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Radiofrequency ablation (RF)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Visually guided laser balloon ablation (VGLB) with negative APT
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Visually guided laser balloon ablation (VGLB) with positive APT
Number of subjects: 50

Group type: COMPARATOR
Intervention: Radiofrequency ablation (RF) with positive APT
Number of subjects: 50

Group type: COMPARATOR
Intervention: Radiofrequency ablation (RF) with negative APT
Number of subjects: 50
Study: 85119806

Group type: EXPERIMENTAL
Intervention: Treatment for Schistosoma haematobium infection
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 35334844

Group type: EXPERIMENTAL
Intervention: Short web-based sugar-rich food screener (SRFS)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Validated web-based 7-day dietary record
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both assessment tools (SRFS and 7-day dietary record)
Number of subjects: 80
Study: 32912103

Group type: EXPERIMENTAL
Intervention: Analgesic medication on most days
Number of subjects: 14155

Group type: EXPERIMENTAL
Intervention: Interference with sleep
Number of subjects: 14155

Group type: EXPERIMENTAL
Intervention: Interference with walking
Number of subjects: 14155

Group type: EXPERIMENTAL
Intervention: Interference with daily activities
Number of subjects: 14155
Study: 32467522

Group type: EXPERIMENTAL
Intervention: IV ketorolac (60 mg/2 ml)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control (IV saline bolus)
Number of subjects: 55
Study: 32324477

Group type: EXPERIMENTAL
Intervention: Whey protein supplementation plus resistive vibration exercise (NeX)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Resistive vibration exercise (RVE)
Number of subjects: 12

Group type: COMPARATOR
Intervention: No-intervention control (CNT)
Number of subjects: 12

Group type: COMPARATOR
Intervention: No intervention (CNT)
Number of subjects: 12
Study: 35427803

Group type: EXPERIMENTAL
Intervention: PDS 10‐mg/ml
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: PDS 40‐mg/ml
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: PDS 100‐mg/ml
Number of subjects: 220

Group type: COMPARATOR
Intervention: Monthly intravitreal ranibizumab 0.5‐mg injections
Number of subjects: 220

Group type: COMPARATOR
Intervention: PDS 100‐mg/ml vs Monthly ranibizumab
Number of subjects: 220
Study: 34389780

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ) 50 mg
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 33228382

Group type: EXPERIMENTAL
Intervention: Home-based adapted physical activity (APA) during adjuvant care (group A)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Home-based adapted physical activity (APA) after adjuvant care (group B)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Home-based adapted physical activity (APA) during and after specific care (group C)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Comparison of group A and C vs group B
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control group (no APA)
Number of subjects: 94
Study: 35941817

Group type: EXPERIMENTAL
Intervention: Maternal adjustment enhancement program using mobile-based education for 4 weeks
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 45
Study: 33764642

Group type: EXPERIMENTAL
Intervention: PO‐001 (sustained-release cysteamine bitartrate) 600 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cystagon® (immediate-release cysteamine)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Procysbi® (delayed-release cysteamine)
Number of subjects: 0
Study: 32020706

Group type: EXPERIMENTAL
Intervention: 12 weeks Circuit Resistance Training (CRT)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Non-exercising wait-list control
Number of subjects: 51
Study: 32102263

Group type: EXPERIMENTAL
Intervention: Beetroot juice (BJ) 70 mL
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 13
Study: 36368262

Group type: EXPERIMENTAL
Intervention: Defatted flaxseed flour biscuits
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control biscuits
Number of subjects: 51
Study: 34407579

Group type: EXPERIMENTAL
Intervention: Functional axillary dissection based on lymphatic drainage (FUND)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Axillary lymph node dissection (ALND)
Number of subjects: 168
Study: 33096810

Group type: EXPERIMENTAL
Intervention: Calorie-restricted high protein diet (HPD) (30% calorie intake)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Calorie-restricted normal protein diet (NPD) (15% calorie intake)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both diets (HPD and NPD)
Number of subjects: 80
Study: 34980260

Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 577

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 577
Study: 33499913

Group type: EXPERIMENTAL
Intervention: IXE Q4W monotherapy
Number of subjects: 455

Group type: COMPARATOR
Intervention: IXE with concomitant MTX
Number of subjects: 455

Group type: EXPERIMENTAL
Intervention: IXE Q2W monotherapy
Number of subjects: 455
Study: 35157727

Group type: COMPARATOR
Intervention: Standard secondary distribution (control) group
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Secondary distribution with monetary incentives (SD-M) group
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Secondary distribution with monetary incentives plus peer referral (SD-M-PR) group
Number of subjects: 309
Study: 34538333

Group type: EXPERIMENTAL
Intervention: Ultrafast SARS-CoV-2 viral enrichment and enzymatic extraction method
Number of subjects: 0
Study: 32307932

Group type: EXPERIMENTAL
Intervention: Single dose of low-level laser therapy (LLLT) 1 hour before the insertion of elastomeric separators
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Double dose of low-level laser therapy (LLLT) 1 hour before and immediately after the insertion of elastomeric separators
Number of subjects: 36
Study: 33143559

Group type: EXPERIMENTAL
Intervention: ANDALE intervention (10-week home-based obesity prevention program)
Number of subjects: 50
Study: 33241302

Group type: EXPERIMENTAL
Intervention: Robot-assisted minimally invasive esophagectomy (RAMIE)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Open transthoracic esophagectomy (OTE)
Number of subjects: 109
Study: 35348875

Group type: EXPERIMENTAL
Intervention: MedDiet
Number of subjects: 802

Group type: COMPARATOR
Intervention: Low-Fat Diet
Number of subjects: 802
Study: 34181361

Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 44
Study: 32893026

Group type: EXPERIMENTAL
Intervention: Ultrasonography feedback with verbal guidance
Number of subjects: 20

Group type: COMPARATOR
Intervention: Verbal guidance alone
Number of subjects: 20
Study: 35019731

Group type: EXPERIMENTAL
Intervention: Cladribine tablets
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 33274683

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24 IU)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 34537623

Group type: EXPERIMENTAL
Intervention: Oxytocin (OT)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 32087339

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR) for 8 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Escitalopram for 8 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Escitalopram
Number of subjects: 0
Study: 35086493

Group type: EXPERIMENTAL
Intervention: PTSD group
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 32
Study: 33754212

Group type: EXPERIMENTAL
Intervention: Structured stress management program (8-week duration)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 61
Study: 35678643

Group type: EXPERIMENTAL
Intervention: Cerebral malaria (CM)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Severe malarial anemia (SMA)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Community children (CC)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Oxidative stress biomarkers
Number of subjects: 156
Study: 34119067

Group type: EXPERIMENTAL
Intervention: Pembrolizumab alone or with chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cetuximab with chemotherapy
Number of subjects: 0
Study: 32761955

Group type: EXPERIMENTAL
Intervention: DA-9701
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study: 35264216

Group type: EXPERIMENTAL
Intervention: Laparoscopic liver resection
Number of subjects: 250

Group type: COMPARATOR
Intervention: Open liver resection
Number of subjects: 250
Study: 34780486

Group type: EXPERIMENTAL
Intervention: Postoperative Anaesthetic Care Unit (PACU) pathway with SAMPE model
Number of subjects: 5333

Group type: COMPARATOR
Intervention: Historical controls (no intervention)
Number of subjects: 5333
Study: 35496038

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (AER)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Combined exercise (COM)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Resistance exercise (RES)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control session
Number of subjects: 20
Study: 33172240

Group type: EXPERIMENTAL
Intervention: Laparoscopic Roux‐en‐Y gastric bypass
Number of subjects: 135

Group type: COMPARATOR
Intervention: Lifestyle intervention
Number of subjects: 135
Study: 36385378

Group type: EXPERIMENTAL
Intervention: MTA Fillapex
Number of subjects: 88

Group type: COMPARATOR
Intervention: AH Plus
Number of subjects: 88
Study: 34560503

Group type: EXPERIMENTAL
Intervention: Supervised machine learning methods for artefact detection in FOT measurements
Number of subjects: 155

Group type: COMPARATOR
Intervention: Manual breath selection by trained operators
Number of subjects: 155
Study: 32424361

Group type: EXPERIMENTAL
Intervention: Therapeutic administration of a single amino acid to experimentally infected mice
Number of subjects: 0

Group type: COMPARATOR
Intervention: Experimental malaria (control group)
Number of subjects: 0
Study: 35762397

Group type: EXPERIMENTAL
Intervention: Smartphone app
Number of subjects: 138

Group type: COMPARATOR
Intervention: Printed brochures
Number of subjects: 138
Study: 33993746

Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Daily rating strategy
Number of subjects: 0
Study: 32545555

Group type: EXPERIMENTAL
Intervention: High meat and refined grains diet (HMD)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Energy-matched diet high in whole grain, dairy, nuts and legumes (HWD)
Number of subjects: 51
Study: 35863012

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery (n=84)
Number of subjects: 391

Group type: COMPARATOR
Intervention: Open surgery (n=84)
Number of subjects: 391
Study: 33016306

Group type: EXPERIMENTAL
Intervention: Heavy-decreasing drinking group (n = 255, 27.27%)
Number of subjects: 935

Group type: EXPERIMENTAL
Intervention: Moderate-stable drinking group (n = 353, 37.75%)
Number of subjects: 935

Group type: EXPERIMENTAL
Intervention: Low-stable drinking group (n = 327, 34.97%)
Number of subjects: 935
Study: 32871910

Group type: EXPERIMENTAL
Intervention: Modified Mahuang-Fuzi-Xixin decoction
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study: 34611052

Group type: EXPERIMENTAL
Intervention: Caffeine (CAF) 6 mg/kg of body mass
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (PLA) (maltodextrin)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Caffeine (CAF)
Number of subjects: 16
Study: 33648441

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.6μg/kg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.8μg/kg
Number of subjects: 120

Group type: COMPARATOR
Intervention: Normal saline (NS)
Number of subjects: 120
Study: 32819465

Group type: EXPERIMENTAL
Intervention: PADN (Pulmonary artery denervation)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Medical therapy with riociguat (MED group)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: PADN
Number of subjects: 50

Group type: COMPARATOR
Intervention: MED group
Number of subjects: 50
Study: 36336248

Group type: EXPERIMENTAL
Intervention: Centrally-administered system-wide implementation + local-tailored implementation
Number of subjects: 12

Group type: COMPARATOR
Intervention: Centrally-administered system-wide implementation only
Number of subjects: 12
Study: 34334377

Group type: EXPERIMENTAL
Intervention: Dry Needling (DN)
Number of subjects: 21
Study: 34837418

Group type: EXPERIMENTAL
Intervention: Fixed-dose combination tablet of mosapride 5 mg, pancreatin 170 mg, and simethicone 125 mg
Number of subjects: 65

Group type: COMPARATOR
Intervention: Single-component mosapride tablets (reference product)
Number of subjects: 65
Study: 34729851

Group type: EXPERIMENTAL
Intervention: PROVIDENT model predictions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control arm (surveillance information and overdose prevention resources)
Number of subjects: 0
Study: 33110044

Group type: EXPERIMENTAL
Intervention: Fennel seed powder (2 gr, four capsules daily for 8 weeks)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Starch-containing capsules (2 gr, four capsules daily for 8 weeks)
Number of subjects: 80
Study: 33347667

Group type: EXPERIMENTAL
Intervention: Mepilex Border Sacrum
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: ALLEVYN Life Sacrum
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Optifoam Gentle Sacrum
Number of subjects: 12

Group type: COMPARATOR
Intervention: No dressing
Number of subjects: 12
Study: 36434348

Group type: EXPERIMENTAL
Intervention: Immediate implants (type 1)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Delayed implants (type 4)
Number of subjects: 25
Study: 33983993

Group type: EXPERIMENTAL
Intervention: Formula with Lactobacillus paracasei ssp. paracasei strain F19 (F19)
Number of subjects: 579

Group type: EXPERIMENTAL
Intervention: Formula with bovine milk fat globule membranes (MFGM)
Number of subjects: 579

Group type: COMPARATOR
Intervention: Standard formula (SF)
Number of subjects: 579

Group type: COMPARATOR
Intervention: Breastfed (BF) infants
Number of subjects: 579
Study: 34049101

Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 292

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 292
Study: 32700956

Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy for Seasonal Affective Disorder (CBT-SAD)
Number of subjects: 177

Group type: COMPARATOR
Intervention: Light Therapy (LT)
Number of subjects: 177
Study: 34655997

Group type: EXPERIMENTAL
Intervention: Radiologist-patient consultation of US results
Number of subjects: 109

Group type: COMPARATOR
Intervention: No radiologist-patient consultation of US results
Number of subjects: 109
Study: 34556516

Group type: EXPERIMENTAL
Intervention: Nature hiking
Number of subjects: 26

Group type: COMPARATOR
Intervention: Urban hiking
Number of subjects: 26
Study: 35671774

Group type: EXPERIMENTAL
Intervention: Fulvestrant plus capivasertib
Number of subjects: 140

Group type: COMPARATOR
Intervention: Fulvestrant plus placebo
Number of subjects: 140
Study: 32484623

Group type: EXPERIMENTAL
Intervention: 1% colloidal oat eczema cream
Number of subjects: 61

Group type: COMPARATOR
Intervention: Standard moisturizer
Number of subjects: 61
Study: 35945486

Group type: EXPERIMENTAL
Intervention: Lidocaine infusion
Number of subjects: 64

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 64
Study: 34972764

Group type: EXPERIMENTAL
Intervention: emoTIC programme
Number of subjects: 385
Study: 35392461

Group type: EXPERIMENTAL
Intervention: Behavioral nudges (social peer comparison nudge, maintenance of professional certification incentive nudge, prior participation nudge)
Number of subjects: 421

Group type: EXPERIMENTAL
Intervention: Prior participation nudge
Number of subjects: 421

Group type: EXPERIMENTAL
Intervention: Nudges (pooled analysis)
Number of subjects: 421

Group type: COMPARATOR
Intervention: Control group (no nudges)
Number of subjects: 421
Study: 34510141

Group type: EXPERIMENTAL
Intervention: Synthetic CBD 20 to 30 mg daily for 12 weeks
Number of subjects: 136

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 136
Study: 33939897

Group type: EXPERIMENTAL
Intervention: l-carnitine (50 mg/kg/day, twice a day for three months)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 32773375

Group type: EXPERIMENTAL
Intervention: Research summary with 2 sources of uncertainty
Number of subjects: 1727

Group type: EXPERIMENTAL
Intervention: Research summary with 3 sources of uncertainty
Number of subjects: 1727

Group type: COMPARATOR
Intervention: Research summary with 1 source of uncertainty
Number of subjects: 1727
Study: 35815880

Group type: EXPERIMENTAL
Intervention: Full-Code
Number of subjects: 17710

Group type: COMPARATOR
Intervention: DNR
Number of subjects: 17710
Study: 32907989

Group type: EXPERIMENTAL
Intervention: LDL-C
Number of subjects: 300000

Group type: EXPERIMENTAL
Intervention: HDL-C
Number of subjects: 300000

Group type: EXPERIMENTAL
Intervention: TGs
Number of subjects: 300000

Group type: EXPERIMENTAL
Intervention: BMI
Number of subjects: 300000

Group type: EXPERIMENTAL
Intervention: T2D
Number of subjects: 300000

Group type: EXPERIMENTAL
Intervention: SBP
Number of subjects: 300000
Study: 32111307

Group type: EXPERIMENTAL
Intervention: Bacillus subtilis (5 × 10^8 cfu/kg)
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Montmorillonite (0.5 g/kg)
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Bacillus subtilis (5 × 10^8 cfu/kg) and Montmorillonite (0.5 g/kg) combination
Number of subjects: 360
Study: 33201054

Group type: EXPERIMENTAL
Intervention: Depatuxizumab mafodotin
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Epithelial debridement, aggressive lubrication, bandage contact lenses, reduction in chemotherapeutic dose to maintenance levels
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Immunohistochemistry of the diseased epithelium
Number of subjects: 2
Study: 32324880

Group type: EXPERIMENTAL
Intervention: Skull base chordomas with vertebrobasilar artery encasement (≥180o encirclement)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group of skull base chordomas with intradural extension
Number of subjects: 48
Study: 35769693

Group type: EXPERIMENTAL
Intervention: Sublingual sufentanil tablet (SST)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Standard-of-care (patient-controlled epidural analgesia [PCEA] or PCA morphine)
Number of subjects: 36
Study: 34742318

Group type: EXPERIMENTAL
Intervention: Rice bran oil (RBO) 30g/day
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sunflower oil (SFO) 30g/day
Number of subjects: 40
Study: 33064415

Group type: EXPERIMENTAL
Intervention: 6 exercise sessions per week
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: 2 exercise sessions per week
Number of subjects: 3

Group type: COMPARATOR
Intervention: Sedentary control
Number of subjects: 3
Study: 33714257

Group type: EXPERIMENTAL
Intervention: Seven ferroptosis-related lncRNAs signature (LINC01503, AC004687.1, AC010973.2, AP001189.3, ARRDC1-AS1, OIP5-AS1, and NCK1-DT)
Number of subjects: 905

Group type: EXPERIMENTAL
Intervention: Seven ferroptosis-related lncRNAs signature
Number of subjects: 905
Study: 32084251

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3220

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 3220

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 3220
Study: 33345583

Group type: EXPERIMENTAL
Intervention: Unified Protocol for Transdiagnostic Treatment of Emotional Disorders for Homeless Women (UPHW)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Wait-list control (WLC)
Number of subjects: 81
Study: 34537385

Group type: EXPERIMENTAL
Intervention: Dapagliflozin (10 mg/day)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Glibenclamide (5 mg/day)
Number of subjects: 97
Study: 33337694

Group type: EXPERIMENTAL
Intervention: Combined strength and endurance training (varied emphasis: Es = 25/75%, SE = 50/50%, Se = 75/25%)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Combined strength and endurance training
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 78
Study: 32976626

Group type: EXPERIMENTAL
Intervention: One standard drink/day increase in alcohol consumption (observational analysis)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Genetically predicted one standard drink/day increase in alcohol consumption (Mendelian randomization analysis)
Number of subjects: 0
Study: 33390020

Group type: EXPERIMENTAL
Intervention: Sinus Tarsi Approach (STA)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Extensile Lateral Approach (ELA)
Number of subjects: 64
Study: 33512807

Group type: EXPERIMENTAL
Intervention: Human milk oligosaccharides (HMOs) - 5g daily dose of 2'‐fucosyllactose and lacto‐N‐neotetraose in a 4:1 mix
Number of subjects: 317
Study: 34773474

Group type: EXPERIMENTAL
Intervention: Erlotinib + momelotinib (200 mg QD)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Erlotinib + momelotinib (100 mg BID)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Erlotinib + momelotinib (various doses)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Erlotinib
Number of subjects: 11
Study: 33592831

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 171
Study: 35142931

Group type: EXPERIMENTAL
Intervention: Remimazolam
Number of subjects: 64

Group type: COMPARATOR
Intervention: Desflurane
Number of subjects: 64
Study: 33724062

Group type: EXPERIMENTAL
Intervention: Second MRI screening round
Number of subjects: 3436

Group type: COMPARATOR
Intervention: First MRI screening round
Number of subjects: 3436